293 results
Page 3 of 15
8-K
EX-99.1
fejnidf9lf96b6si090
5 Aug 21
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
4:01pm
8-K
EX-10.1
atjva 8wl2z8
12 Jul 21
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
11:13am
8-K
EX-99.1
fx5wu6fd
12 Jul 21
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
11:13am
8-K
EX-99.1
fuhxwai9
10 Jun 21
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
4:07pm
8-K
EX-99.1
qnx 231not5z28j
8 Jun 21
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
8:41am
8-K
EX-99.1
yrlg9km11yzljw6 9o7
1 Jun 21
Regulation FD Disclosure
10:52am
8-K
EX-99.1
a0ga39e51tnr tqh7
6 May 21
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
4:01pm
8-K
EX-99.1
or1luw
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
8-K
EX-99.3
zfnhubbuuutov32c8qxl
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
8-K
EX-99.4
x12sc61g3ts1g
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
8-K
EX-99.2
teajkp a5h
12 Apr 21
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
8:33am
S-3ASR
qyp9 ap4cdeqdjaf
12 Mar 21
Automatic shelf registration
4:10pm
S-3ASR
EX-4.3
xmql0li6bm10t
12 Mar 21
Automatic shelf registration
4:10pm
S-3ASR
EX-4.4
q46s78n4xl
12 Mar 21
Automatic shelf registration
4:10pm
8-K
EX-99.1
58slogdci1gt tq6r4s
25 Feb 21
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
4:02pm